Related Experiment Video
Updated: May 20, 2026
13:19
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Patented prostate cancer biomarkers
Lisa Murphy1, R William Watson1
1University College Dublin School of Medicine and Medical Science, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin 4, Ireland.
Nature Reviews. Urology
|July 4, 2012
Summary
New prostate cancer biomarkers are needed for accurate diagnosis and treatment selection. Current methods lack specificity, highlighting the need for reliable, patentable biomarkers for clinical utility and commercialization.
Area of Science:
- Oncology
- Biomarker Discovery
- Medical Diagnostics
Background:
- Prostate cancer is the most common cancer diagnosed in men globally.
- Existing diagnostic methods, such as serum prostate-specific antigen (PSA) testing, have limitations in specificity and sensitivity for assessing disease aggressiveness and guiding treatment.
- There is a critical need for novel biomarkers to improve early diagnosis, prognosis, and prediction of treatment response in prostate cancer patients.
Purpose of the Study:
- To highlight the unmet need for improved diagnostic and prognostic biomarkers in prostate cancer.
- To discuss the requirements for clinical utility of biomarkers, including commercialization potential.
- To examine the role of intellectual property protection, such as patents, in biomarker development.
Main Methods:
- Literature review on current prostate cancer diagnostics.
- Analysis of the challenges in biomarker development and validation.
- Discussion of the interplay between scientific innovation, intellectual property, and clinical adoption.
Main Results:
- Current diagnostic tools for prostate cancer are insufficient for precise clinical decision-making.
- Development of new biomarkers is hindered by the need for validation and commercial viability.
- Patenting is a key strategy for protecting biomarker intellectual property, encouraging investment.
Conclusions:
- Reliable biomarkers are essential for advancing prostate cancer care through early detection and personalized treatment.
- Overcoming the gap between biomarker discovery and clinical implementation requires addressing commercialization and validation challenges.
- Patented biomarkers show promise but require rigorous validation to ensure clinical utility and patient benefit.
